LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

Inicio・Lista de Acciones・MacroGenics Inc

MacroGenics Inc

Abierto

Sector Salud

3.47 -6.22

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

3.33

Máximo

3.76

Métricas clave
By Trading Economics
Ingresos	-52M
Ventas	-1.6M 9.1M
BPA	-0.84
Margen de beneficio	-573.264
Empleados	339
EBITDA	-49M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 meses	+95.95 upside

Dividendos
By Dow Jones
Próximas Ganancias	4 nov 2024

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	-6.6M 219M
Apertura anterior	9.69
Cierre anterior	3.47

Noticias sobre sentimiento de mercado

By Acuity

63%

37%

298 / 365 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bullish Evidence

3.56 / 3.745 Soporte y Resistencia

MacroGenics Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

14 sept 2024, 01:45 UTC

Ganancias

Preview -- Barron's

13 sept 2024, 20:03 UTC

Principales Noticias

Walgreens to Pay $106.8 Million Over Alleged Fraudulent Healthcare Billings

15 sept 2024, 23:47 UTC

Charlas de Mercado

Gold Edges Higher Amid Mild Dollar Weakness -- Market Talk

15 sept 2024, 23:03 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

15 sept 2024, 23:03 UTC

Charlas de Mercado

Australian Bond Traders Watchful as Fed Easing Nears -- Market Talk

15 sept 2024, 16:52 UTC

Principales Noticias

Boeing Machinist Strike Adds Cash Crunch to New CEO's Rescue Mission -- WSJ

15 sept 2024, 09:30 UTC

Principales Noticias

Interest Rates Are Too High. The Fed Should Cut by a Half Point. -- WSJ

15 sept 2024, 07:00 UTC

Principales Noticias

World's Biggest Hedge Fund Sells Apple, Eli Lilly Stock, and Buys Microsoft, Moderna -- Barrons.com

14 sept 2024, 14:09 UTC

Principales Noticias

Disney, DirecTV Reach Deal, Ending Blackout of ABC, ESPN -- Update 1 -- WSJ

14 sept 2024, 13:25 UTC

Principales Noticias

Disney, DirecTV Reach Deal, Ending Blackout of ABC, ESPN -- WSJ

14 sept 2024, 09:30 UTC

Principales Noticias

Why a Fed Rate Cut Won't Solve the Housing Wealth Gap -- WSJ

14 sept 2024, 09:30 UTC

Principales Noticias

Americans Are Falling Behind on Their Bills. Wall Street Is Alarmed. -- WSJ

14 sept 2024, 03:00 UTC

Principales Noticias

What Scared Ford's CEO in China -- WSJ

14 sept 2024, 03:00 UTC

Principales Noticias

What Scared Ford's CEO in China -- WSJ -2-

14 sept 2024, 00:01 UTC

Principales Noticias

Why 96% of Boeing's Machinists Voted to Go on Strike -- Update

13 sept 2024, 21:14 UTC

Principales Noticias

Why 96% of Boeing's Machinists Voted to Go on Strike -- WSJ

13 sept 2024, 21:06 UTC

Principales Noticias

Starliner Astronauts Say NASA Ran Short of Time to Test Boeing Craft -- WSJ

13 sept 2024, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

13 sept 2024, 20:47 UTC

Charlas de Mercado

Saudi Arabia Credit Outlook Raised to Positive on Economic Investments -- Market Talk

13 sept 2024, 20:44 UTC

Adquisiciones, fusiones, absorciones

Schlumberger Stock Was Once as Hot as Nvidia. Why It's a Buy. -- Barrons.com

13 sept 2024, 20:41 UTC

Principales Noticias

Berkshire Hathaway's Stock Is So Rich Even Berkshire Is Buying Less of It -- Update

13 sept 2024, 20:31 UTC

Ganancias

These Stocks Moved the Most Today: Adobe, Boeing, Trump Media, Oracle, Uber, RH, Moderna, Etsy, and More -- Barrons.com

13 sept 2024, 20:13 UTC

Adquisiciones, fusiones, absorciones

BlackRock: Expects to Close Previously Announced Acquisition of Global Infrastructure Partners on Oct 1 >BLK

13 sept 2024, 20:10 UTC

Adquisiciones, fusiones, absorciones

BlackRock Announces Expected Closing Date For Acquisition Of Global Infrastructure Partners >BLK

13 sept 2024, 20:02 UTC

Adquisiciones, fusiones, absorciones

CGI Completes Acquisition Of Aeyon, Expands Capabilities For National Security And Civilian Agency Missions >GIB

13 sept 2024, 20:02 UTC

Adquisiciones, fusiones, absorciones

CGI Completes Acquisition Of Aeyon, Expands Capabilities For National Security And Civilian Agency Missions >GIB

13 sept 2024, 19:44 UTC

Charlas de Mercado

Treasury Yields Fall as Odds of 50bp Fed Cut Rise -- Market Talk

13 sept 2024, 19:20 UTC

Charlas de Mercado

Crude-Oil Futures End Week With Small Gains -- Market Talk

13 sept 2024, 19:09 UTC

Charlas de Mercado

U.S. Natural-Gas Futures Post Weekly Gain -- Market Talk

13 sept 2024, 18:01 UTC

Charlas de Mercado

Gold Analysts Call For New Leg Of Rally -- Market Talk

Comparación entre iguales

Cambio de precio

MacroGenics Inc Esperado

Precio Objetivo

By TipRanks

95.95% repunte

Estimación a 12 meses

Media 7.25 USD 95.95%

Máximo 14 USD

Mínimo 4 USD

De acuerdo con 12 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para MacroGenics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

12 ratings

Comprar

Mantener

Vender

De acuerdo con 12 analistas que ofrecen calificaciones bursátiles a para MacroGenics Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

3.56 / 3.745Soporte y Resistencia

Recent bullish events outweigh bearish events.

All events are bearish.

Sentimiento

By Acuity

298 / 365 Clasificación en Salud

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de MacroGenics Inc

MacroGenics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies. It has a pipeline of product candidates in human clinical testing, primarily as treatments for different types of cancers, which are created using its technology platforms. Its clinical product candidate, margetuximab, has been enhanced using its Fc Optimization platform. The Company is also developing several product candidates targeting B7-H3, a protein in the B7 family of immune regulator proteins. The Company's product candidates also include enoblituzumab and MGD009, MGC018, MGD006 (flotetuzumab), MGD007, MGD011 (duvortuxizumab), PF-06671008 and MGD010.